Progyny, Inc. (PGNY)
NASDAQ: PGNY · IEX Real-Time Price · USD
28.33
-0.05 (-0.18%)
At close: Jul 2, 2024, 4:00 PM
28.19
-0.14 (-0.49%)
After-hours: Jul 2, 2024, 7:52 PM EDT
Progyny Employees
Progyny had 566 employees as of December 31, 2023. The number of employees increased by 166 or 41.50% compared to the previous year.
Employees
566
Change (1Y)
166
Growth (1Y)
41.50%
Revenue / Employee
$1,958,095
Profits / Employee
$108,228
Market Cap
2.70B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 566 | 166 | 41.50% |
Dec 31, 2022 | 400 | 87 | 27.80% |
Dec 31, 2021 | 313 | 103 | 49.05% |
Dec 31, 2020 | 210 | 43 | 25.75% |
Dec 31, 2019 | 167 | 30 | 21.90% |
Dec 31, 2018 | 137 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Envista Holdings | 12,800 |
Azenta | 3,500 |
Twist Bioscience | 919 |
ADMA Biologics | 624 |
ACADIA Pharmaceuticals | 598 |
MorphoSys AG | 524 |
TG Therapeutics | 264 |
Rhythm Pharmaceuticals | 226 |
PGNY News
- 6 days ago - Progyny, Inc. to Host 2024 Inaugural Investor Day - GlobeNewsWire
- 8 days ago - Progyny, Inc. Announces Enhanced Global Services with Acquisition of Apryl - GlobeNewsWire
- 21 days ago - Fertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of Growth - PRNewsWire
- 4 weeks ago - Progyny, Inc. to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Progyny's board approves another $100 million stock buyback - Market Watch
- 5 weeks ago - Progyny, Inc. Announces Additional Share Repurchase Program - GlobeNewsWire
- 7 weeks ago - Progyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024 - GlobeNewsWire
- 7 weeks ago - Progyny's stock plunges as demand for IVF treatments drops after Alabama ruling - Market Watch